155 related articles for article (PubMed ID: 10761961)
1. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study.
Langman LJ; Ray JG; Evrovski J; Yeo E; Cole DE
Arch Intern Med; 2000 Apr; 160(7):961-4. PubMed ID: 10761961
[TBL] [Abstract][Full Text] [Related]
2. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.
Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642
[TBL] [Abstract][Full Text] [Related]
3. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.
Manns BJ; Burgess ED; Hyndman ME; Parsons HG; Schaefer JP; Scott-Douglas NW
Am J Kidney Dis; 1999 Oct; 34(4):669-77. PubMed ID: 10516348
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.
Falcon CR; Cattaneo M; Panzeri D; Martinelli I; Mannucci PM
Arterioscler Thromb; 1994 Jul; 14(7):1080-3. PubMed ID: 8018663
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives.
Beaumont V; Malinow MR; Sexton G; Wilson D; Lemort N; Upson B; Beaumont JL
Atherosclerosis; 1992 Jun; 94(2-3):147-52. PubMed ID: 1632868
[TBL] [Abstract][Full Text] [Related]
6. Hyperhomocyst(e)inemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion.
Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Quehenberger F; Semmelrock J; Haas A
Ophthalmology; 2002 Jun; 109(6):1105-9. PubMed ID: 12045051
[TBL] [Abstract][Full Text] [Related]
7. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis.
Yoo JH; Chung CS; Kang SS
Stroke; 1998 Dec; 29(12):2478-83. PubMed ID: 9836754
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
9. Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans.
Yoo JH; Park JE; Hong KP; Lee SH; Kim DK; Lee WR; Park SC
Thromb Res; 1999 Apr; 94(1):45-52. PubMed ID: 10213180
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Schmidt AM; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1998 May; 21(5):841-8. PubMed ID: 9589252
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy.
Weger M; Stanger O; Deutschmann H; Simon M; Renner W; Schmut O; Semmelrock J; Haas A
Br J Ophthalmol; 2001 Jul; 85(7):803-6. PubMed ID: 11423453
[TBL] [Abstract][Full Text] [Related]
12. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.
Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM
Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocyst(e)inemia and Chlamydia pneumoniae IgG seropositivity in patients with coronary artery disease.
Stanger OH; Semmelrock HJ; Rehak P; Tiran B; Meinitzer A; Rigler B; Tiran A
Atherosclerosis; 2002 May; 162(1):157-62. PubMed ID: 11947909
[TBL] [Abstract][Full Text] [Related]
14. Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis.
Lee YK; Kwon YJ; Yoon JW; Oh KS; Cha DR; Cho WY; Huh K; Pyo HJ; Kim HK
J Korean Med Sci; 1999 Apr; 14(2):193-8. PubMed ID: 10331567
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocyst(e)inemia is a risk factor of secondary vascular events in stroke patients.
Del Ser T; Barba R; Herranz AS; Seijas V; López-Manglano C; Domingo J; Pondal M
Cerebrovasc Dis; 2001 Aug; 12(2):91-8. PubMed ID: 11490102
[TBL] [Abstract][Full Text] [Related]
16. Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome.
Joven J; Arcelús R; Camps J; Ordóñez-Llanos J; Vilella E; González-Sastre F; Blanco-Vaca F
J Mol Med (Berl); 2000; 78(3):147-54. PubMed ID: 10868477
[TBL] [Abstract][Full Text] [Related]
17. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1997 Dec; 20(12):1880-6. PubMed ID: 9405911
[TBL] [Abstract][Full Text] [Related]
18. Hyperhomocyst(e)inemia is associated with carotid atherosclerosis.
Lupattelli G; Rufini S; Locati EH; Lombardini R; Ciuffetti G; Siepi D; Mannarino E
Angiology; 1999 Oct; 50(10):823-30. PubMed ID: 10535721
[TBL] [Abstract][Full Text] [Related]
19. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review.
Ray JG; Laskin CA
Placenta; 1999 Sep; 20(7):519-29. PubMed ID: 10452905
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate.
Verhoef P; Stampfer MJ; Buring JE; Gaziano JM; Allen RH; Stabler SP; Reynolds RD; Kok FJ; Hennekens CH; Willett WC
Am J Epidemiol; 1996 May; 143(9):845-59. PubMed ID: 8610698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
